Page last updated: 2024-08-22

trimetazidine and Non-alcoholic Fatty Liver Disease

trimetazidine has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Li, C; Li, X; Liu, X; Lu, S; Wu, C; Zhang, Y; Zhou, H	1

Other Studies

1 other study(ies) available for trimetazidine and Non-alcoholic Fatty Liver Disease

Article	Year
Trimetazidine improves hepatic lipogenesis and steatosis in non‑alcoholic fatty liver disease via AMPK‑ChREBP pathway. Molecular medicine reports, 2020, Volume: 22, Issue:3 Topics: AMP-Activated Protein Kinases; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Body Weight; Diet, High-Fat; Disease Models, Animal; Forkhead Box Protein O1; Gene Expression Regulation; Hep G2 Cells; Humans; Lipogenesis; Male; Mice; Non-alcoholic Fatty Liver Disease; Palmitates; Signal Transduction; Trimetazidine	2020

Article

Year

Trimetazidine improves hepatic lipogenesis and steatosis in non‑alcoholic fatty liver disease via AMPK‑ChREBP pathway.

Molecular medicine reports, 2020, Volume: 22, Issue:3

Topics: AMP-Activated Protein Kinases; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Body Weight; Diet, High-Fat; Disease Models, Animal; Forkhead Box Protein O1; Gene Expression Regulation; Hep G2 Cells; Humans; Lipogenesis; Male; Mice; Non-alcoholic Fatty Liver Disease; Palmitates; Signal Transduction; Trimetazidine

2020